Do Traders Think Ideaya Biosciences Inc (IDYA) Can Turn Around Tuesday?

The market has been down on Ideaya Biosciences Inc (IDYA) stock recently. IDYA gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Ideaya Biosciences Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on IDYA!

See Full IDYA Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With IDYA Stock Today?

Ideaya Biosciences Inc (IDYA) stock is trading at $42.51 as of 12:19 PM on Tuesday, Mar 26, a rise of $0.20, or 0.47% from the previous closing price of $42.31. The stock has traded between $42.31 and $43.23 so far today. Volume today is below average. So far 138,737 shares have traded compared to average volume of 764,324 shares.

More About Ideaya Biosciences Inc

IDEAYA Biosciences Inc an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. Click Here to get the full Stock Report for Ideaya Biosciences Inc stock.